Fixed-Dose Every-Other-Week Capecitabine and Oxaliplatin for Refractory Squamous Cell Carcinoma of the Head and Neck

Fixed-dose capecitabine and oxaliplatin combination on an every-other-week schedule showed activity in refractory SCCHN. The simplicity and toxicity profile of this regimen compares favorably with other commonly used chemotherapies and should be tested in larger studies.